Valneva (NASDAQ:VALN) Upgraded to Hold at Zacks Investment Research

Valneva (NASDAQ:VALNGet Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday, Zacks.com reports.

According to Zacks, “Valneva SE is a specialty vaccine company. It is focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. Valneva SE is based in Saint-Herblain, France. “

Separately, UBS Group lowered Valneva from a “neutral” rating to a “sell” rating in a research note on Wednesday, December 22nd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $37.00.

Shares of NASDAQ VALN traded up $0.75 during trading hours on Tuesday, reaching $34.37. 8,901 shares of the stock were exchanged, compared to its average volume of 9,150. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.59 and a quick ratio of 1.25. Valneva has a 52 week low of $24.16 and a 52 week high of $67.84. The stock’s fifty day simple moving average is $34.45 and its 200 day simple moving average is $40.80.

A number of large investors have recently modified their holdings of VALN. Alps Advisors Inc. acquired a new stake in shares of Valneva in the 4th quarter valued at $3,369,000. Granite Point Capital Management L.P. acquired a new stake in shares of Valneva in the 3rd quarter valued at $376,000. Millennium Management LLC acquired a new stake in shares of Valneva in the 2nd quarter valued at $259,000. Finally, Morgan Stanley acquired a new stake in shares of Valneva in the 3rd quarter valued at $97,000. 0.50% of the stock is currently owned by institutional investors and hedge funds.

Valneva Company Profile (Get Rating)

Valneva SE, a specialty vaccine company, focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; and DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium.

Recommended Stories

Get a free copy of the Zacks research report on Valneva (VALN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Valneva (NASDAQ:VALN)

Receive News & Ratings for Valneva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valneva and related companies with MarketBeat.com's FREE daily email newsletter.